Peri-implantitis - Reconstructive Surgical Therapy

Peri-Implantitis Clinical Trial

Official title:

Reconstructive Surgical Therapy of Peri-implantitis-related Osseous Defects. A Multicenter Randomized Controlled Clinical Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03077061
• Other study ID #: 1192-16
• Status: Active, not recruiting
• Phase: N/A
• Start date: April 1, 2017
• Est. completion date: March 14, 2026

Study information

• Verified date: September 2023
• Source: Göteborg University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The project will evaluate the potential benefit of the use of bone replacement graft as an adjunct to surgical therapy of peri-implantitis. The project will be conducted as a two-armed randomized controlled clinical trial of 5-year duration in 7 clinical centers. 140 systemically healthy patients diagnosed with peri-implantitis will randomly assigned to be treated with or without bone replacement graft. Outcome measures include assessments of inflammation, probing depth, recession, radiological parameters and PROMs.

Description:

Objective The overall objective of the project is to evaluate the clinical efficacy of the use of a bone substitute material in reconstructive surgical therapy of peri-implantitis-associated osseous defects.

Hypothesis: The use of a bone substitute material in reconstructive therapy of peri-implantitis increases the likelihood to achieve treatment success.

Relevance for clinical practice The project will provide significant contribution to the understanding of outcomes using reconstructive procedures in treatment of peri-implantitis.

Study population, design and treatment procedures The project will be conducted as a two-armed randomized controlled clinical trial of 5-year duration in 7 clinical centers. 140 systemically healthy patients with implants ≥1 year in function and diagnosed with advanced peri-implantitis at ≥1 implants will be enrolled.

Inclusion criteria Age ≥ 18 years

≥1 implant (≥1 year of function) presenting with PPD ≥7 mm and BoP/Pus. Confirmed bone loss ≥3 mm at same implant(s)

Exclusion criteria Treated for peri-implantitis during previous 6 months Intake of systemic or local antibiotics during previous 6 months Systemic conditions affecting peri-implant tissues Systemic conditions impeding surgical intervention

Surgical procedures Surgical procedures will be performed one month after a baseline examination and initiation of plaque control. Three days before surgery a 10-day systemic antibiotic regimen will be initiated. Full thickness flaps will be elevated and inflamed tissues will be removed. The implant surfaces will be cleaned with mini-gauze soaked in saline. The osseous defect should be ≤4 mm wide and >3 mm deep. The defect should in addition to the mesial and distal bone walls preferably exhibit at least a lingual or a buccal bone wall. The randomly assigned treatment strategy, stratified for smoking, will be revealed after debridement. Test procedure: The defect will be filled with Bio-Oss Collagen® and the flaps will be sutured to their previous position. Control procedure: Flaps will be sutured to their previous position. Sutures will be removed 2 weeks after treatment, followed by a 6-week control. Clinical examinations will be performed at 6, 12, 24, 36, 48 and 60 months after therapy. Maintenance therapy will be provided based on individual needs.

Clinical assessments One calibrated examiner in each clinical center will perform the assessments. The following variables will be assessed at four sites around the implant: Plaque, probing pocket depth (PPD), bleeding on probing (BoP), probing attachment level (PAL) and recession (REC).

Treatment success Treatment success will be defined as the absence of BoP/Pus, PPD ≤5 mm and ≤1 mm recession. Peri-implant sites showing BoP and PPD ≥6 mm at re-examination will be scheduled for further treatment. Patient-related outcome variables will be assessed at baseline and follow-up and include esthetic and functional appreciation, pain or discomfort.

Radiographic assessments Intra-oral radiographs will be obtained prior to surgery (baseline) and at 1-, 3- and 5-year re-examinations. Analysis of radiographs will be performed by specialists in oral-maxillofacial radiology. The examiners will be blinded to treatment procedures. The assessment will include defect fill and crestal bone support.

Power calculation A total of 122 patients (61 per group) will provide a power of 80% with alpha set at 0.05 to detect a difference of 1 mm in mean PPD change between groups, given a SD of 1.97 (Carcuac et al., 2016). 140 individuals will be included to compensate for drop-out.

Data analysis Mean changes for the various variables and the proportion of sites fulfilling the criteria for treatment success will be calculated. A multilevel model with the clinical center as the highest level and the implant as the lowest will be built to test the influence of measured factors on the outcomes and to compensate for potential clustering of data. Data analysis including multilevel modeling will be conducted in collaboration with a biostatistician.

Schedule of investigational events

1. Screening and identification of subjects.

2. Baseline clinical examination of implants selected for the study. Case presentation and reinforcement of self-performed plaque control. Assessment of PROM. Professional mechanical infection control.

3. Radiographic examination prior to surgical therapy (within 4 weeks).

4. Surgical therapy including test and control treatment procedures at study sites.

5. 2 weeks - suture removal. Assessment of PROM.

6. 6 weeks - professional supra-mucosal cleaning and reinforcement of oral hygiene.

7. 6 months - clinical examination.

8. 12 months - clinical and radiological examination. Assessment of PROM.

9. 24 months - clinical examination.

10. 36 months - clinical and radiological examination. Assessment of PROM.

11. 48 months - clinical examination.

12. 60 months - clinical and radiological examination. Assessment of PROM.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 140
• Est. completion date: March 14, 2026
• Est. primary completion date: March 14, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years

• =1 implant (=1 year of function) presenting with PPD =7 mm and BoP/Pus.

• Confirmed bone loss =3 mm at same implant(s)

Exclusion Criteria:

• Treated for peri-implantitis during previous 6 months

• Intake of systemic or local antibiotics during previous 6 months

• Systemic conditions affecting peri-implant tissues

• Systemic conditions impeding surgical intervention

Related Conditions & MeSH terms

• Peri-Implantitis

Intervention

Procedure:
• Open flap debridement
Open flap debridement using saline as irrigation

Device:
• Bone replacement graft
Open flap debridement using saline as irrigation including a grafting procedure withBio-Oss Collagen®.

Locations

Country	Name	City	State
Sweden	Department of Periodontology, Institute of Odontology	Göteborg

Sponsors (2)

Lead Sponsor	Collaborator
Göteborg University	Osteology Foundation

Country where clinical trial is conducted

Sweden, 

References & Publications (8)

Albouy JP, Abrahamsson I, Persson LG, Berglundh T. Implant surface characteristics influence the outcome of treatment of peri-implantitis: an experimental study in dogs. J Clin Periodontol. 2011 Jan;38(1):58-64. doi: 10.1111/j.1600-051X.2010.01631.x. Epub 2010 Nov 24. — View Citation

Carcuac O, Abrahamsson I, Charalampakis G, Berglundh T. The effect of the local use of chlorhexidine in surgical treatment of experimental peri-implantitis in dogs. J Clin Periodontol. 2015 Feb;42(2):196-203. doi: 10.1111/jcpe.12332. Epub 2015 Jan 20. — View Citation

Carcuac O, Derks J, Charalampakis G, Abrahamsson I, Wennstrom J, Berglundh T. Adjunctive Systemic and Local Antimicrobial Therapy in the Surgical Treatment of Peri-implantitis: A Randomized Controlled Clinical Trial. J Dent Res. 2016 Jan;95(1):50-7. doi: 10.1177/0022034515601961. Epub 2015 Aug 18. — View Citation

Derks J, Schaller D, Hakansson J, Wennstrom JL, Tomasi C, Berglundh T. Effectiveness of Implant Therapy Analyzed in a Swedish Population: Prevalence of Peri-implantitis. J Dent Res. 2016 Jan;95(1):43-9. doi: 10.1177/0022034515608832. — View Citation

Jepsen K, Jepsen S, Laine ML, Anssari Moin D, Pilloni A, Zeza B, Sanz M, Ortiz-Vigon A, Roos-Jansaker AM, Renvert S. Reconstruction of Peri-implant Osseous Defects: A Multicenter Randomized Trial. J Dent Res. 2016 Jan;95(1):58-66. doi: 10.1177/0022034515610056. Epub 2015 Oct 8. — View Citation

Khoshkam V, Chan HL, Lin GH, MacEachern MP, Monje A, Suarez F, Giannobile WV, Wang HL. Reconstructive procedures for treating peri-implantitis: a systematic review. J Dent Res. 2013 Dec;92(12 Suppl):131S-8S. doi: 10.1177/0022034513509279. Epub 2013 Oct 24. — View Citation

Roccuzzo M, Gaudioso L, Lungo M, Dalmasso P. Surgical therapy of single peri-implantitis intrabony defects, by means of deproteinized bovine bone mineral with 10% collagen. J Clin Periodontol. 2016 Mar;43(3):311-8. doi: 10.1111/jcpe.12516. Epub 2016 Mar 9. — View Citation

Wohlfahrt JC, Lyngstadaas SP, Ronold HJ, Saxegaard E, Ellingsen JE, Karlsson S, Aass AM. Porous titanium granules in the surgical treatment of peri-implant osseous defects: a randomized clinical trial. Int J Oral Maxillofac Implants. 2012 Mar-Apr;27(2):401-10. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment success (year 1)	Absence of bleeding/suppuration on probing, probing depth =5 mm and =1 mm recession of mucosal margin	Assessed at year 1
Primary	Treatment success (year 3)	Absence of bleeding/suppuration on probing, probing depth =5 mm and =1 mm recession of mucosal margin	Assessed at year 3
Primary	Treatment success (year 5)	Absence of bleeding/suppuration on probing, probing depth =5 mm and =1 mm	Assessed at year 5
Secondary	Radiographic outcomes	Defect fill and crestal bone support	Assessed at 1, 3 and 5 years
Secondary	Patient-reported outcomes	Patient-reported outcomes assessed by questionnaire and in relation to baseline	Prior to intervention and at 1, 3 and 5 years